References
- Persistence Market Research. Antibody drug conjugates market: global industry analysis and forecast 2017–2025. [Accessed 04 Apr 2018]. https://www.persistencemarketresearch.com/market-research/antibody-drug-conjugates-market.asp
- Maruani A, Smith MEB, Miranda E, Chester KA, Chudasama V, Caddick S, et al. A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy. Nat Commun. 2015 Mar 31;6:6645. doi:https://doi.org/10.1038/ncomms7645. PMID: 25824906.
- Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. MAbs. 2014 Jan-Feb;6(1):34–11. doi:https://doi.org/10.4161/mabs.27022. PMID: 24423619.
- Storz U. Antibody-drug conjugates: intellectual property considerations. mAbs. 2015 7;6:989–1009. doi:https://doi.org/10.1080/19420862.2015.1082019.
- Jackson DY. Processes for constructing homogeneous antibody drug conjugates. Org Process Res Dev. 2016:205852–866. doi:https://doi.org/10.1021/acs.oprd.6b00067.
- Grawunder U, Barth S. Next generation antibody drug conjugates (ADCs) and immunotoxins. Chapter 5 Enzyme-based strategies to generate site-specifically conjugated antibody drug conjugates. Springer; 2017.
- Kline T, Steiner AR, Penta K, Sato AK, Hallam TJ, Yin G. Methods to make homogenous antibody drug conjugates. Pharm Res. 2015;32(11):3480–93. doi:https://doi.org/10.1007/s11095-014-1596-8.
- Jain N, Smith SW, Ghone S, Tomczuk B. Current ADC linker chemistry. Pharm Res. 2015;32(11):3526–40. doi:https://doi.org/10.1007/s11095-015-1657-7.
- Sochaj AM, Świderska KW, Otlewski J. Current methods for the synthesis of homogeneous antibody–drug conjugates. Biotechnol Adv. 2015;33(6):775–784. doi:https://doi.org/10.1016/j.biotechadv.2015.05.001.
- Agarwal P, Bertozzi CR. Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjug Chem. 2015;26:176–192. doi:https://doi.org/10.1021/bc5004982.
- Behrens CR, Liu B. Methods for site-specific drug conjugation to antibodies. mAbs. 2014;6:46–53. doi:https://doi.org/10.4161/mabs.26632.
- Dan N, Setua S, Kashyap V, Khan S, Jaggi M, Yallapu M and Chauhan S. Antibody-drug conjugates for cancer therapy: chemistry to clinical implications. Pharmaceuticals (Basel). 2018;11(2):32. doi:https://doi.org/10.3390/ph11020032.
- Bhakta S, Raab H, Junutula JR. Engineering THIOMABs for site-specific conjugation of thiol-reactive linkers. Methods Mol Biol. 2013;1045:189–203.
- Junutula J, Hans Erickson Rachana V, Ohri S, Bhakta H, Raab R, Vandlen JJ, Erickson H, A high-throughput conjugation strategy for the selection of THIOMABTM antibodies with desired properties for antibody-drug conjugation; 2015; AACR 106th Annu. Meet. in Philadelphia
- Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008;26:925–932. doi:https://doi.org/10.1038/nbt.1480.
- Kim EG, Kim KM. Strategies and advancement in antibody-drug conjugate optimization for targeted cancer therapeutics. Biomolecules Ther. 2015;23(6):493–509. doi:https://doi.org/10.4062/biomolther.2015.116.
- Behrens CR, Ha EH, Chinn LL, Bowers S, Probst G, Fitch-Bruhns M, Monteon J, Valdiosera A, Bermudez A, Liao-Chan S, et al. Antibody–drug conjugates (ADCs) derived from interchain cysteine cross-linking demonstrate improved homogeneity and other pharmacological properties over conventional heterogeneous ADCs. Mol Pharm. 2015;12(11):3986–3998. doi:https://doi.org/10.1021/acs.molpharmaceut.5b00432.
- Dennler P, Fischer E, Schibli R. Antibody conjugates: from heterogeneous populations to defined reagents. Antibodies. 2015;4:197–224. doi:https://doi.org/10.3390/antib4030197.
- Badescu G, Bryant P, Bird M, Henseleit K, Swierkosz J, Parekh V, Tommasi R, Pawlisz E, Jurlewicz K, Farys M, et al. Bridging disulfides for stable and defined antibody drug conjugates. Bioconjug Chem. 2014 18;25(6):1124–36. doi:https://doi.org/10.1021/bc500148x.
- Badescu G, Bryant P, Swierkosz J, Khayrzad F, Pawlisz E, Farys M, Cong Y, Muroni M, Rumpf N, Brocchini S, et al. A new reagent for stable thiol-specific conjugation. Bioconjug Chem. 2014;25(3):460–469. doi:https://doi.org/10.1021/bc400245v.
- Shinmi D, Taguchi E, Iwano J, Yamaguchi T, Masuda K, Enokizono J, Shiraishi Y. One-step conjugation method for site-specific antibody–drug conjugates through reactive cysteine-engineered antibodies. Bioconjug Chem. 2016;27(5):1324–1331. doi:https://doi.org/10.1021/acs.bioconjchem.6b00133.
- Feige MJ, Hendershot LM, Buchner J. How antibodies fold. Trends Biochem Sci. 2010;35(4):189–98. doi:https://doi.org/10.1016/j.tibs.2009.11.005.
- Miret RRJ, Roura A, Moreno C, Arboix G, Farràs M, Cancelliere D, Di Gesù C, Casablancas A, Lecina M, Cairó JJ, “PO276 comparison of bicistronic and tricistonic expression strategies for trastuzumab and trastuzumab-interferon-a2b production in CHO and HEK293 cells; 2017; 25th ESACT meeting in Lausanne.
- Lyon R, Setter J, Bovee T, Doronina SO, Hunter JH, Anderson ME, Balasubramanian CL, Duniho SM, Leiske CI, Li F, et al. Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-dug-conjugates. Nat Biotechnol. 2014;32:1059–1062. doi:https://doi.org/10.1038/nbt.2968.
- Ehkirch A, D’Atri V, Rouviere F, Hernandez-Alba O, Goyon A, Colas O, Sarrut M, Beck A, Guillarme D, Heinisch S, et al. An online four-dimensional HIC×SEC-IM×MS methodology for proof-of-concept characterization of antibody drug conjugates. Anal Chem. 2018;90(3):1578–1586. doi:https://doi.org/10.1021/acs.analchem.7b02110.
- Said N, Gahoual R, Kuhn L, Beck A, Yannis-Nicolas F. Structural characterization of antibody drug conjugate by a combination of intact, middle-up and bottom-up techniques using sheathless capillary electrophoresis - Tandem mass spectrometry as nanoESI infusion platform and separation method. Anal Chim Acta. 2016;918:50–9. doi:https://doi.org/10.1016/j.aca.2016.03.006.
- Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-LaFord HD, Jonas M, Anderson ME, Setter JR, Senter PD, et al. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol. 2015;33:733–735. doi:https://doi.org/10.1038/nbt.3212.
- Burke PJ, Hamilton JZ, Jeffrey SC, Hunter JH, Doronina SO, Okeley NM, Miyamoto JB, Anderson ME, Stone IJ, Ulrich ML, et al. Optimization of a PEGylated glucuronide-monomethylauristatin E linker for antibody–drug conjugates. Mol Cancer Ther. 2017;16:116–123. doi:https://doi.org/10.1158/1535-7163.
- Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9:33–46. doi:https://doi.org/10.1007/s13238-016-0323-0.
- Román R, Miret J, Scalia F, Casablancas A, Lecina M, Cairó JJ. Enhancing heterologous protein expression and secretion in HEK293 cells by means of combination of CMV promoter and IFNα2 signal peptide. J Biotechnol. 2016;239:57–60. doi:https://doi.org/10.1016/j.jbiotec.2016.10.005.
- Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074–D1082. doi:https://doi.org/10.1093/nar/gkx1037.
- Haryadi R, Ho S, Kok YJ, Pu HX, Zheng L, Pereira NA, Li B, Bi X, Goh L-T, Yang Y, et al. Optimization of heavy chain and light chain signal peptides for high level expression of therapeutic antibodies in CHO cells. PLoS One. 2015 Feb 23;10(2):e0116878. doi:https://doi.org/10.1371/journal.pone.0116878.
- Chin JX, Chung BKS, Lee DY. Codon Optimization OnLine (COOL): a web-based multi-objective optimization platform for synthetic gene design. Bioinformatics. 2014;30(15):2210–2212. doi:https://doi.org/10.1093/bioinformatics/btu192.